By using direct peptide isolation from purified gp96 and microsequencing, his team successfully isolated an HBV-specific peptide associated with heat-shock protein gp96 from HBV-infected liver cancer tissues, and showed that a virus-specific peptide was bound to gp96 derived from liver tissues of patients with HBV-induced hepatocellular carcinoma (Meng et al., 2001), which laid a solid theoretical foundation for the development of engineered tumor vaccines against hepatocellular carcinoma and chronic HBV infection, as well as drugs for chronic hepatitis B and liver cancer. This evidence concerns the gene HSP90B1 and liver cancer.